AI
LLY icon

Axiom Investors’s Eli Lilly LLY Stock Holding History

Axiom Investors’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-46,846
Closed -$36.2M – 152
2024
Q4 		$36.2M Sell
46,846
-276,540
-86% -$229M 0.27% 45
2024
Q3 		$287M Sell
323,386
-130,745
-29% -$118M 2.52% 11
2024
Q2 		$411M Sell
454,131
-36,623
-7% -$29.3M 3.58% 8
2024
Q1 		$382M Sell
490,754
-228,387
-32% -$163M 3.33% 7
2023
Q4 		$419M Buy
719,141
+69,447
+11% +$40.5M 4.11% 7
2023
Q3 		$349M Buy
649,694
+2,378
+0.4% +$1.23M 5.02% 5
2023
Q2 		$304M Buy
647,316
+44,963
+7% +$18.9M 4.52% 5
2023
Q1 		$207M Buy
602,353
+1,303
+0.2% +$439K 3.41% 8
2022
Q4 		$220M Buy
601,050
+20,736
+4% +$7.35M 4.33% 4
2022
Q3 		$188M Buy
580,314
+259,657
+81% +$82.3M 3.94% 3
2022
Q2 		$104M Buy
+320,657
New +$96.3M 3.12% 9

Other funds holding LLY

PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Axiom Investors's LLY Position: Q1 2025 in Review

Axiom Investors sold out of Eli Lilly (LLY) in Q1 2025, closing a stake of 46,846 shares — an estimated $36.2M sold.

Axiom Investors first reported a position in LLY in Q2 2022 and held it in 11 quarters. The position peaked at $419M in Q4 2023. 3,919 funds tracked by Wall St. Rank hold LLY as of Q1 2025.

  • Axiom Investors reported no remaining Eli Lilly position as of Q1 2025 after selling out during the quarter.
  • Axiom Investors sold 46,846 Eli Lilly shares in Q1 2025, an estimated $36.2M.
  • Axiom Investors first reported a position in Eli Lilly in Q2 2022 and held it in 11 quarters.
  • Axiom Investors's Eli Lilly position peaked at $419M in Q4 2023.
  • 3,919 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2025.

Based on Axiom Investors's 13F filing for Q1 2025, filed 14 May 2025.